OPT Opthea

Opthea’s Wet AMD Program to be Featured at FLORetina 2024

Opthea’s Wet AMD Program to be Featured at FLORetina 2024

MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. FLORetina aims to provide cutting-edge insights on research and clinical development from world-leading experts in the field of medical retina, retinal surgery, and imaging.

Details are as follows:

Session:Retina Futura 1: Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical Updates
Date:Friday, December 6, 2024, 11:25 AM CET
Presentation:Beyond VEGF-A Inhibition: Will Blocking VEGF-C and VEGF-D Lead to Better Outcomes?
Presenter:Professor Adnan Tufail, MBBS, MD, FRCOphth
Program:
  

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, , and ShORe, ) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at and follow us on and .

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

Investor Inquiries

PJ Kelleher 

LifeSci Advisors, LLC 

Email:

Phone: 617-430-7579 

Media Inquiries

Silvana Guerci-Lena

NorthStream Global Partners

Email:

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399, Email: Web:

Source: Opthea Limited



EN
26/11/2024

Underlying

OPTOpthea

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Opthea

 PRESS RELEASE
Free
OPT OPTHEA

Opthea Announces Decision to Discontinue Wet AMD Trials

Opthea Announces Decision to Discontinue Wet AMD Trials ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing...

March 31, 2025 1 EN
 PRESS RELEASE
Free
OPT OPTHEA

Opthea Announces COAST Phase 3 Trial Topline Results

Opthea Announces COAST Phase 3 Trial Topline Results COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular de...

March 24, 2025 1 EN
 PRESS RELEASE
Free
OPT OPTHEA

Opthea Announces Phase 2b Wet AMD Publication

Opthea Announces Phase 2b Wet AMD Publication Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the publication of sozinibercept Phase 2b...

March 3, 2025 1 EN
 PRESS RELEASE
Free
OPT OPTHEA

Opthea Reports Half Year Results and Business Updates

Opthea Reports Half Year Results and Business Updates Cash and cash equivalents of $131.9M as of December 31, 2024 Cash runway extends through anticipated topline data readouts of COAST (early 2Q CY25) and ShORe (mid-CY25) MELBOURNE, Australia and PRINCETON, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced financial results for the six m...

February 28, 2025 1 EN
 PRESS RELEASE
Free
OPT OPTHEA

Opthea Completes Drug Product PPQ Campaign

Opthea Completes Drug Product PPQ Campaign Three consecutive commercial-scale drug product batches successfully produced Supports potential sozinibercept BLA filing in 1H CY2026 MELBOURNE, Australia and PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the completion of its drug product Process Performance Qualification (PPQ)...

February 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch